Beneficial for patients with AML receiving anthracyclines, with no impact on event-free, overall survival
TUESDAY, May 12, 2020 (HealthDay News) — For pediatric patients with acute myeloid leukemia (AML), dexrazoxane preserves cardiac function without affecting survival, according to a study published online April 28 in the Journal of Clinical Oncology.
Kelly D. Getz, Ph.D., from the Children’s Hospital of Philadelphia, and colleagues conducted a multicenter study of all pediatric patients with AML without high allelic ratio FLT3/ITD treated between 2011 and 2016. Patients were followed for a median of 3.5 years. Dexrazoxane was administered at the discretion of treating physicians; per protocol, anthracyclines were to be withheld if there was evidence of left ventricular systolic dysfunction (LVSD).
Data were included for 1,014 patients; 96 were dexrazoxane-exposed at every anthracycline course and 918 were never exposed. The researchers found significantly smaller ejection fraction and shortening fraction declines for dexrazoxane-exposed versus unexposed patients across courses; dexrazoxane-exposed patients also had a lower risk for LVSD (26.5 versus 42.2 percent; hazard ratio, 0.55; 95 percent confidence interval, 0.36 to 0.86; P = 0.009). Compared with unexposed patients, dexrazoxane-exposed patients had similar five-year event-free survival (49 versus 45.1 percent) and overall survival (65 versus 61.9 percent); there was a suggestion of lower treatment-related mortality with dexrazoxane (5.7 versus 12.7 percent).
“A more complete understanding of the underlying biology of anthracycline-associated cardiotoxicity and effective interventions will improve both the cardiovascular and oncologic outcomes for children with cancer,” the authors write.
Bayer HealthCare Pharmaceuticals and Takeda Pharmaceuticals International provided study drugs.
Copyright © 2020 HealthDay. All rights reserved.
